Stoke Therapeutics, Inc. (STOK) Earnings Call Analysis

NASDAQ · Unknown · Unknown

11/25

Growth 2 Margin 2 Expansion 3 Platform 2 Financial 2

latest quarter score

Earnings Reports

11
Stoke Therapeutics (STOK) Q2 2026: EMPEROR Enrollment Hits 162, Extending Runway to 2028 Launch
August 04, 2026
11
Stoke Therapeutics (STOK) Q1 2026: EMPEROR Phase 3 Nears 150-Patient Enrollment, Four-Year OLE Data Deepens Label Leverage
May 08, 2026
11
Stoke Therapeutics (STOK) Q3 2025: R&D Spend Jumps 70% as Phase III Enrollment Surges Past 200 Patients
November 05, 2025
12
Stoke Therapeutics (STOK) Q2 2025: 36-Month Cognition Gains Anchor Zareva-Nursen’s Disease-Modifying Case
August 12, 2025

Browse all companies